Revolution Medicines recorded $198 million in domestic revenue for its new therapy within five weeks of regulatory clearance. The company revealed on Wednesday that over 5,000 patients have initiated treatment so far. Chief Commercial Officer Anthony Mancini characterized the debut as a strong domestic launch during an earnings call. These early results nearly doubled the most optimistic forecasts heading into the third-quarter financial release.
Key points
The commercial performance positions the newly approved treatment among the strongest can…: The commercial performance positions the newly approved treatment among the strongest cancer drug launches to date.
Financial analysts and investors are revising their future commercial projections upward…: Financial analysts and investors are revising their future commercial projections upward based on rapid early sales.
Executive Anthony Mancini confirmed on the third-quarter earnings call that domestic adop…: Executive Anthony Mancini confirmed on the third-quarter earnings call that domestic adoption remains exceptionally strong.
Sources checked by our analysis pipeline: 1
The commercial debut of Revolution Medicines’ pancreatic cancer drug Rasonque was eye-popping and jaw-dropping: $198 million in sales in just five weeks following the U.S. approval of the groundbreaking pan-RAS inhibitor. More than 5,000 patients have already been treated with the drug, the company said Wednesday evening.
“The U.S. launch of Rasonque is off to a strong start,” said Revolution Chief Commercial Officer Anthony Mancini, on the company’s earnings call — perhaps the understatement of the year in commercial biotech.
Rasonque’s sales performance was nearly double even the most bullish investor estimates heading into the company’s third-quarter earnings announcement. It might be too early to call Rasonque the best cancer drug launch in history, but it’s certainly close, and investors are now re-evaluating their forecasts for what lies ahead.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Investors aggressively dumped stock in the online travel platform after the company delivered disappointing quarterly financial metrics alongside an unexpected leadership shakeup. The sharp decline underscores mounting market anxiety regarding future growth and operational stability as executive leadership prepares to change hands.
Strong demand from younger demographics has prompted the luxury fashion parent company to update its forecasts. The surge in consumer purchases reflects resilient interest in primary handbag lines among newer market cohorts. This momentum indicates sustained customer engagement across key retail segments despite broader industry shifts.
The robotics firm completed a merger with a special purpose acquisition company to fund its business operations and reach the market faster. Leadership anticipates that securing this public status will grant the enterprise a distinct competitive edge against industry rivals. However, mounting deficits cast doubt on whether the business can sustain its ongoing operational momentum.